AKT and C-MYC signaling are the major oncogenic driver pathways for HCC and hepatic activation of AKT or C-MYC is sufficient to induce HCC in mouse models through HDT-mediated tail vein injection17 (Supplementary Fig. 4e). This evidence concerns the gene AKT1 and hepatocellular carcinoma.